scispace - formally typeset
Search or ask a question
Author

Guy A. Rouleau

Bio: Guy A. Rouleau is an academic researcher from Montreal Neurological Institute and Hospital. The author has contributed to research in topics: Genome-wide association study & Amyotrophic lateral sclerosis. The author has an hindex of 129, co-authored 884 publications receiving 65892 citations. Previous affiliations of Guy A. Rouleau include Utrecht University & University of Helsinki.


Papers
More filters
Journal ArticleDOI
Janice L. Farlow1, Hai Lin1, Laura Sauerbeck2, Dongbing Lai1, Daniel L. Koller1, Elizabeth W. Pugh3, Kurt N. Hetrick3, Hua Ling3, Rachel Kleinloog4, Pieter van der Vlies5, Patrick Deelen5, Morris A. Swertz5, Bon H. Verweij4, Luca Regli6, Luca Regli4, Gabriel J.E. Rinkel4, Ynte M. Ruigrok4, Kimberly F. Doheny3, Yunlong Liu1, Tatiana Foroud1, Tatiana Foroud7, Joseph P. Broderick2, Daniel Woo2, Brett M. Kissela2, Dawn Kleindorfer2, Alex Schneider2, Mario Zuccarello2, Andrew J. Ringer2, Ranjan Deka2, Robert D. Brown8, John Huston8, Irene Mesissner8, David O. Wiebers8, Adnan I. Qureshi9, Peter A. Rasmussen10, E. Sander Connolly11, Ralph L. Sacco11, Marc Malkaff12, Troy D. Payner, Gary G. Ferguson13, E. Francois Aldrich14, Guy A. Rouleau15, Craig S. Anderson, Edward W. Mee, Graeme J. Hankey16, Neville W. Knuckey17, Peter L. Reilly, John Laidlaw18, Paul D'Urso19, Jeffrey V. Rosenfeld19, Michael K. Morgan20, Nicholas W. C. Dorsch21, Michael Besser22, H. Hunt Batjer23, M. T. Richard24, Amin B. Kassam25, Gary K. Steinberg26, S. Claiborne Johnston27, Nerissa U. Ko27, Steven L. Giannotta28, Neal F. Kassell29, Bradford B. Worrall29, Kenneth C. Lui29, Aaron S. Dumont29, David L. Tirschell30, Anthony M. Kaufmann31, Winfield S. Fisher32, Khaled Aziz33, Arthur L. Day34, Rose Du34, Christopher S. Ogilvy34, Stephen B. Lewis35, Kieran P. Murphy3, Martin G. Radvany3, Dheerah Gandhi3, Lynda D. Lisabeth36, Aditya S. Pandey36, Lewis B. Morgenstern36, Colin P. Derdeyn37, Carl D. Langefeld38, Joan E. Bailey-Wilson3 
24 Mar 2015-PLOS ONE
TL;DR: It is demonstrated that sequencing of densely affected families permits exploration of the role of rare variants in a relatively common disease such as IA, although there are important study design considerations for applying sequencing to complex disorders.
Abstract: Genetic risk factors for intracranial aneurysm (IA) are not yet fully understood. Genomewide association studies have been successful at identifying common variants; however, the role of rare variation in IA susceptibility has not been fully explored. In this study, we report the use of whole exome sequencing (WES) in seven densely-affected families (45 individuals) recruited as part of the Familial Intracranial Aneurysm study. WES variants were prioritized by functional prediction, frequency, predicted pathogenicity, and segregation within families. Using these criteria, 68 variants in 68 genes were prioritized across the seven families. Of the genes that were expressed in IA tissue, one gene (TMEM132B) was differentially expressed in aneurysmal samples (n=44) as compared to control samples (n=16) (false discovery rate adjusted p-value=0.023). We demonstrate that sequencing of densely affected families permits exploration of the role of rare variants in a relatively common disease such as IA, although there are important study design considerations for applying sequencing to complex disorders. In this study, we explore methods of WES variant prioritization, including the incorporation of unaffected individuals, multipoint linkage analysis, biological pathway information, and transcriptome profiling. Further studies are needed to validate and characterize the set of variants and genes identified in this study.

261 citations

Journal ArticleDOI
TL;DR: This work identifies PTPRD as the fourth genome-wide significant locus for RLS, and two independent SNPs in the 5′ UTR of splice variants expressed predominantly in the central nervous system showed highly significant P values.
Abstract: We identified association of restless legs syndrome (RLS) with PTPRD at 9p23-24 in 2,458 affected individuals and 4,749 controls from Germany, Austria, Czechia and Canada. Two independent SNPs in the 5' UTR of splice variants expressed predominantly in the central nervous system showed highly significant P values (rs4626664, P(nominal/lambda corrected) = 5.91 x 10(-10), odds ratio (OR) = 1.44; rs1975197, P(nominal/lambda corrected) = 5.81 x 10(-9), OR = 1.31). This work identifies PTPRD as the fourth genome-wide significant locus for RLS.

260 citations

Journal ArticleDOI
Liping Hou1, Urs Heilbronner2, Urs Heilbronner3, Franziska Degenhardt4, Mazda Adli5, Kazufumi Akiyama6, Nirmala Akula1, Raffaella Ardau, Bárbara Arias7, Lena Backlund8, Claudio E. M. Banzato9, Antoni Benabarre7, Susanne Bengesser10, Abesh Kumar Bhattacharjee11, Joanna M. Biernacka12, Armin Birner10, Clara Brichant-Petitjean13, Elise T. Bui1, Pablo Cervantes14, Guo-Bo Chen15, Hsi-Chung Chen16, Caterina Chillotti, Sven Cichon17, Sven Cichon4, Scott R. Clark18, Francesc Colom7, David A. Cousins19, Cristiana Cruceanu20, Piotr M. Czerski21, Clarissa de Rosalmeida Dantas9, Alexandre Dayer22, Bruno Etain23, Peter Falkai2, Andreas J. Forstner4, Louise Frisén8, Janice M. Fullerton24, Janice M. Fullerton25, Sébastien Gard, Julie Garnham26, Fernando S. Goes27, Paul Grof, Oliver Gruber3, Ryota Hashimoto28, Joanna Hauser21, Stefan Herms4, Stefan Herms17, Per Hoffmann17, Per Hoffmann4, Andrea Hofmann4, Stéphane Jamain23, Esther Jiménez7, Jean-Pierre Kahn29, Layla Kassem1, Sarah Kittel-Schneider30, Sebastian Kliwicki21, Barbara König, Ichiro Kusumi31, N. Lackner10, Gonzalo Laje1, Mikael Landén32, Mikael Landén33, Catharina Lavebratt8, Marion Leboyer, Susan G. Leckband8, Susan G. Leckband34, Carlos Jaramillo35, Glenda MacQueen36, Mirko Manchia26, Mirko Manchia37, Lina Martinsson32, Manuel Mattheisen38, Michael McCarthy34, Susan L. McElroy39, Marina Mitjans7, Francis M. Mondimore27, Palmiero Monteleone40, Palmiero Monteleone41, Caroline M. Nievergelt11, Markus M. Nöthen4, Urban Ösby8, Norio Ozaki42, Roy H. Perlis43, Andrea Pfennig44, Daniela Reich-Erkelenz2, Guy A. Rouleau45, Peter R. Schofield24, Peter R. Schofield25, K Oliver Schubert18, Barbara W. Schweizer27, Florian Seemüller2, Giovanni Severino37, Tatyana Shekhtman46, Tatyana Shekhtman11, Paul D. Shilling11, Kazutaka Shimoda6, Christian Simhandl, Claire Slaney26, Jordan W. Smoller43, Alessio Squassina37, Thomas Stamm5, Pavla Stopkova47, Sarah K. Tighe48, Sarah K. Tighe49, Alfonso Tortorella40, Gustavo Turecki20, Julia Volkert30, Stephanie H. Witt50, Adam Wright24, L. Trevor Young51, Peter P. Zandi27, James B. Potash49, J. Raymond DePaulo27, Michael Bauer44, Eva Z. Reininghaus10, Tomas Novak47, Jean-Michel Aubry22, Mario Maj40, Bernhard T. Baune18, Philip B. Mitchell24, Eduard Vieta7, Mark A. Frye12, Janusz K. Rybakowski21, Po-Hsiu Kuo16, Tadafumi Kato52, Maria Grigoroiu-Serbanescu, Andreas Reif30, Maria Del Zompo37, Frank Bellivier13, Martin Schalling8, Naomi R. Wray15, John R. Kelsoe11, John R. Kelsoe46, Martin Alda26, Martin Alda47, Marcella Rietschel50, Francis J. McMahon1, Thomas G. Schulze 
United States Department of Health and Human Services1, Ludwig Maximilian University of Munich2, University of Göttingen3, University of Bonn4, Charité5, Dokkyo Medical University6, University of Barcelona7, Karolinska University Hospital8, State University of Campinas9, Medical University of Graz10, University of California, San Diego11, Mayo Clinic12, Paris Diderot University13, McGill University Health Centre14, University of Queensland15, National Taiwan University16, University Hospital of Basel17, University of Adelaide18, Newcastle University19, Douglas Mental Health University Institute20, Poznan University of Medical Sciences21, Geneva College22, French Institute of Health and Medical Research23, University of New South Wales24, Neuroscience Research Australia25, Dalhousie University26, Johns Hopkins University27, Osaka University28, University of Lorraine29, Goethe University Frankfurt30, Hokkaido University31, Karolinska Institutet32, University of Gothenburg33, Veterans Health Administration34, University of Antioquia35, University of Calgary36, University of Cagliari37, Aarhus University38, University of Cincinnati39, University of Naples Federico II40, University of Salerno41, Nagoya University42, Harvard University43, Dresden University of Technology44, Montreal Neurological Institute and Hospital45, United States Department of Veterans Affairs46, National Institutes of Health47, Roy J. and Lucille A. Carver College of Medicine48, University of Iowa49, Heidelberg University50, University of Toronto51, RIKEN Brain Science Institute52
TL;DR: A genome-wide association study of lithium response in 2,563 patients collected by 22 participating sites from the International Consortium on Lithium Genetics (ConLiGen); the largest attempted so far finds a single locus of four linked SNPs on chromosome 21 met genome- wide significance criteria for association with lithium response.

258 citations

Journal ArticleDOI
TL;DR: These findings identify mutations in SLC12A6 as the genetic lesion underlying ACCPN and suggest a critical role for SLC 12A6 in the development and maintenance of the nervous system.
Abstract: The K–Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum

255 citations

Journal Article
TL;DR: Clinical data provide conclusive evidence that a phenotype/genotype correlation exists for certain NF2 mutations, and when individuals harboring protein-truncating mutations are compared with cases with single codon alterations, a significant correlation with clinical outcome is observed.
Abstract: The gene predisposing to neurofibromatosis type 2 (NF2) on human chromosome 22 has revealed a wide variety of different mutations in NF2 individuals. These patients display a marked variability in clinical presentation, ranging from very severe disease with numerous tumors at a young age to a relatively mild condition much later in life. To investigate whether this phenotypic heterogeneity is determined by the type of mutation in NF2, we have collected clinical information on 111 NF2 cases from 73 different families on whom we have performed mutation screening in this gene. Sixty-seven individuals (56.2%) from 41 of these kindreds revealed 36 different putative disease-causing mutations. These include 26 proposed protein-truncating alterations (frameshift deletions/insertions and nonsense mutations), 6 splice-site mutations, 2 missense mutations, 1 base substitution in the 3' UTR of the NF2 cDNA, and a single 3-bp in-frame insertion. Seventeen of these mutations are novel, whereas the remaining 19 have been described previously in other NF2 individuals or sporadic tumors. When individuals harboring protein-truncating mutations are compared with cases with single codon alterations, a significant correlation (P < .001) with clinical outcome is observed. Twenty-four of 28 patients with mutations that cause premature truncation of the NF2 protein, schwannomin, present with severe phenotypes. In contrast, all 16 cases from three families with mutations that affect only a single amino acid have mild NF2. These data provide conclusive evidence that a phenotype/genotype correlation exists for certain NF2 mutations.

248 citations


Cited by
More filters
28 Jul 2005
TL;DR: PfPMP1)与感染红细胞、树突状组胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作�ly.
Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1(PfPMP1)与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员,通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

18,940 citations

Journal ArticleDOI
01 Jun 1990-Cell
TL;DR: A model for the genetic basis of colorectal neoplasia that includes the following salient features is presented, which may be applicable to other common epithelial neoplasms, in which tumors of varying stage are more difficult to study.

11,576 citations

Journal ArticleDOI
TL;DR: A unified analytic framework to discover and genotype variation among multiple samples simultaneously that achieves sensitive and specific results across five sequencing technologies and three distinct, canonical experimental designs is presented.
Abstract: Recent advances in sequencing technology make it possible to comprehensively catalogue genetic variation in population samples, creating a foundation for understanding human disease, ancestry and evolution. The amounts of raw data produced are prodigious and many computational steps are required to translate this output into high-quality variant calls. We present a unified analytic framework to discover and genotype variation among multiple samples simultaneously that achieves sensitive and specific results across five sequencing technologies and three distinct, canonical experimental designs. Our process includes (1) initial read mapping; (2) local realignment around indels; (3) base quality score recalibration; (4) SNP discovery and genotyping to find all potential variants; and (5) machine learning to separate true segregating variation from machine artifacts common to next-generation sequencing technologies. We discuss the application of these tools, instantiated in the Genome Analysis Toolkit (GATK), to deep whole-genome, whole-exome capture, and multi-sample low-pass (~4×) 1000 Genomes Project datasets.

10,056 citations

Journal ArticleDOI
04 Mar 1993-Nature
TL;DR: Tight genetic linkage between FALS and a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion O–2 to O2 and H2O2 is reported.
Abstract: Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord. Its cause is unknown and it is uniformly fatal, typically within five years. About 10% of cases are inherited as an autosomal dominant trait, with high penetrance after the sixth decade. In most instances, sporadic and autosomal dominant familial ALS (FALS) are clinically similar. We have previously shown that in some but not all FALS pedigrees the disease is linked to a genetic defect on chromosome 21q (refs 8, 9). Here we report tight genetic linkage between FALS and a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion O2.- to O2 and H2O2 (ref. 10). Given this linkage and the potential role of free radical toxicity in other neurodenegerative disorders, we investigated SOD1 as a candidate gene in FALS. We identified 11 different SOD1 missense mutations in 13 different FALS families.

6,733 citations

Journal ArticleDOI
TL;DR: It is found that ras-gene mutations occurred in 58 percent of adenomas larger than 1 cm and in 47 percent of carcinomas, which are consistent with a model of colorectal tumorigenesis in which the steps required for the development of cancer often involve the mutational activation of an oncogene coupled with the loss of several genes that normally suppress tumors.
Abstract: Because most colorectal carcinomas appear to arise from adenomas, studies of different stages of colorectal neoplasia may shed light on the genetic alterations involved in tumor progression. We looked for four genetic alterations (ras-gene mutations and allelic deletions of chromosomes 5, 17, and 18) in 172 colorectal-tumor specimens representing various stages of neoplastic development. The specimens consisted of 40 predominantly early-stage adenomas from 7 patients with familial adenomatous polyposis, 40 adenomas (19 without associated foci of carcinoma and 21 with such foci) from 33 patients without familial polyposis, and 92 carcinomas resected from 89 patients. We found that ras-gene mutations occurred in 58 percent of adenomas larger than 1 cm and in 47 percent of carcinomas. However, ras mutations were found in only 9 percent of adenomas under 1 cm in size. Sequences on chromosome 5 that are linked to the gene for familial adenomatous polyposis were not lost in adenomas from the patients with polyposis but were lost in 29 to 35 percent of adenomas and carcinomas, respectively, from other patients. A specific region of chromosome 18 was deleted frequently in carcinomas (73 percent) and in advanced adenomas (47 percent) but only occasionally in earlier-stage adenomas (11 to 13 percent). Chromosome 17p sequences were usually lost only in carcinomas (75 percent). The four molecular alterations accumulated in a fashion that paralleled the clinical progression of tumors. These results are consistent with a model of colorectal tumorigenesis in which the steps required for the development of cancer often involve the mutational activation of an oncogene coupled with the loss of several genes that normally suppress tumorigenesis.

6,309 citations